Zhuang Aobo, Fang Yuan, Heger Michal, Ma Lijie, Xu Jing, Wang Jiongyuan, Lu Weiqi, Tong Hanxing, Zhou Yuhong, Zhang Yong
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xiamen University Research Center, Retroperitoneal Tumor Committee of Oncology Society of Chinese Medical Association, Xiamen University, Xiamen, Fujian, China.
J Clin Transl Res. 2022 Nov 24;8(6):584-593. eCollection 2022 Dec 29.
No cohort studies have been performed on Chinese primary retroperitoneal sarcoma (RPS) patients. Data derived from western cohort studies may not be directly superimposable on Asian counterparts. Furthermore, the risk factors for survival of RPS are currently unknown for Chinese patients. The objectives were therefore to (1) gain insight into RPS incidence and patient demographics and clinical details; (2) determine the risk factors for overall survival (OS) and disease-free survival (DFS); and (3) critically appraise the Asian cohort data in relation to information obtained in western cohort studies.
In this retrospective cohort study, the health records of patients that had been diagnosed with primary localized RPS with curative intent between 2009 and 2020 were analyzed. Cox proportional hazards analysis was conducted to evaluate the risk factors for OS and DFS.
A total of 261 patients met the inclusion criteria. Ninety-six (36.8%) patients had been diagnosed with well-differentiated liposarcoma, 63 patients (24.1%) with dedifferentiated liposarcoma, 41 patients (15.7%) with leiomyosarcoma (LMS), 22 patients (8.4%) with solitary fibroma, 7 patients (2.7%) with malignant peripheral nerve sheath tumor (MPNST), and 32 patients (12.3%) with another type of RPS. The study further revealed that (1) the 5-y OS and DFS in RPS patients was 67.8% and 51.3%, respectively, with the highest OS and DFS observed in MPNST (100% and 100%, respectively) and the lowest 5-y OS and DFS attributed to LMS (42.6% and 28.9%, respectively); (2) symptoms at presentation, Federal National Cancer Center (FNCLCC) grade, and number of combined resections are independent risk factors in OS; (3) symptoms at presentation, FNCLCC grade, chemotherapy, and hospital length of stay are independent risk factors for DFS; and (4) patients at high risk (symptoms at presentation and high-grade tumors) have less than half the chance of survival at 5 y post-diagnosis than patients with a low-risk profile.
Symptoms at presentation constitute a risk factor for OS and DFS. When combined with tumor grade - another risk factor for both OS and DFS - patients can be classified into a high-risk and low-risk category to gauge a patient's prognosis and, accordingly, frame an optimal clinical trajectory. Moreover, the clinicopathology and overall prognosis of RPS in Asian and Western populations are comparable and hence superimposable.
The present study identifies the risk factors of survival in RPS and suggests symptoms at presentation should be considered in the preoperative consultation and added in prognostic grouping.
尚未对中国原发性腹膜后肉瘤(RPS)患者进行队列研究。来自西方队列研究的数据可能无法直接套用于亚洲患者。此外,中国患者RPS生存的危险因素目前尚不清楚。因此,本研究的目的是:(1)深入了解RPS的发病率、患者人口统计学特征及临床细节;(2)确定总生存(OS)和无病生存(DFS)的危险因素;(3)严格评估亚洲队列数据与西方队列研究所得信息的相关性。
在这项回顾性队列研究中,分析了2009年至2020年间被诊断为原发性局限性RPS且有治愈意向患者的健康记录。采用Cox比例风险分析评估OS和DFS的危险因素。
共有261例患者符合纳入标准。96例(36.8%)患者被诊断为高分化脂肪肉瘤,63例(24.1%)为去分化脂肪肉瘤,41例(15.7%)为平滑肌肉瘤(LMS),22例(8.4%)为孤立性纤维瘤,7例(2.7%)为恶性外周神经鞘瘤(MPNST),32例(12.3%)为其他类型的RPS。该研究还显示:(1)RPS患者的5年OS和DFS分别为67.8%和51.3%,其中MPNST的OS和DFS最高(分别为100%和100%),而LMS的5年OS和DFS最低(分别为42.6%和28.9%);(2)就诊时的症状、法国国立癌症中心(FNCLCC)分级和联合切除的数量是OS的独立危险因素;(3)就诊时的症状、FNCLCC分级、化疗和住院时间是DFS的独立危险因素;(4)高危患者(就诊时出现症状和高级别肿瘤)诊断后5年的生存机会不到低危患者的一半。
就诊时的症状是OS和DFS的危险因素。当与肿瘤分级(OS和DFS的另一个危险因素)相结合时,可将患者分为高危和低危类别,以评估患者的预后,并据此制定最佳临床治疗方案。此外,亚洲和西方人群中RPS的临床病理特征和总体预后具有可比性,因此可以相互套用。
本研究确定了RPS生存的危险因素,并建议在术前咨询中考虑就诊时的症状,并将其纳入预后分组。